Market closed
Hikma Pharmaceuticals/£HIK
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, operating under the ticker HIK, is a multinational pharmaceutical company. Founded in 1978 and headquartered in London, UK, it specializes in developing, manufacturing, and marketing both branded and non-branded generic and in-licensed pharmaceutical products. The company operates within the healthcare sector, focusing on a broad range of therapeutic areas.
Ticker
£HIK
Sector
Trading on
LSE
Industry
Pharmaceuticals
Headquarters
Employees
9,100
Website
HIK Metrics
BasicAdvanced
£4.3B
Market cap
18.93
P/E ratio
£1.02
EPS
0.40
Beta
£0.79
Dividend rate
4.10%
Dividend yield
Price and volume
Market cap
£4.3B
Beta
0.4
52-week high
£21.65
52-week low
£17.50
Average daily volume
420K
Dividend rate
£0.79
Financial strength
Current ratio
1.656
Quick ratio
0.888
Long term debt to equity
46.13
Total debt to equity
55.478
Dividend payout ratio (TTM)
55.79%
Interest coverage (TTM)
9.75%
Management effectiveness
Return on assets (TTM)
9.40%
Return on equity (TTM)
12.88%
Valuation
Price to earnings (TTM)
18.928
Price to revenue (TTM)
1.761
Price to book
1.88
Price to tangible book (TTM)
3.6
Price to free cash flow (TTM)
14.019
Dividend yield (TTM)
4.10%
Growth
Revenue change (TTM)
10.47%
Earnings per share change (TTM)
92.80%
3-year revenue growth (CAGR)
7.55%
3-year earnings per share growth (CAGR)
-14.13%
3-year dividend per share growth (CAGR)
14.96%
What the Analysts think about HIK
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
HIK Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HIK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe
FAQs
What’s the current market cap for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals (HIK) has a market cap of £4.3B as of December 21, 2024.
What is the P/E ratio for Hikma Pharmaceuticals stock?
The price to earnings (P/E) ratio for Hikma Pharmaceuticals (HIK) stock is 18.93 as of December 21, 2024.
Does Hikma Pharmaceuticals stock pay dividends?
Yes, the Hikma Pharmaceuticals (HIK) stock pays dividends to shareholders. As of December 21, 2024, the dividend rate is £0.79 and the yield is 4.1%. Hikma Pharmaceuticals has a payout ratio of 55.79% on a trailing twelve-month basis.
When is the next Hikma Pharmaceuticals dividend payment date?
The next Hikma Pharmaceuticals (HIK) dividend payment date is unconfirmed.
What is the beta indicator for Hikma Pharmaceuticals?
Hikma Pharmaceuticals (HIK) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.